EA200401142A1 - Микронизированный кристаллический тиотропийбромид - Google Patents

Микронизированный кристаллический тиотропийбромид

Info

Publication number
EA200401142A1
EA200401142A1 EA200401142A EA200401142A EA200401142A1 EA 200401142 A1 EA200401142 A1 EA 200401142A1 EA 200401142 A EA200401142 A EA 200401142A EA 200401142 A EA200401142 A EA 200401142A EA 200401142 A1 EA200401142 A1 EA 200401142A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tiotropybromid
micronized crystalline
obtaining
medicinal product
micronized
Prior art date
Application number
EA200401142A
Other languages
English (en)
Other versions
EA007064B1 (ru
Inventor
Хельмут Бендер
Хаген Гребнер
Конрад Шнидлер
Михаэль Йозеф Фридрих Трунк
Михаэль Вальц
Original Assignee
Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27797948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200401142(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг filed Critical Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг
Publication of EA200401142A1 publication Critical patent/EA200401142A1/ru
Publication of EA007064B1 publication Critical patent/EA007064B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Catalysts (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Glass Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Hybrid Cells (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

В заявке описан микронизированный кристаллический (1α,2β,4β,5α,7β)-7-[(гидроксиди-2-тиенилацетил)окси]-9,9-диметил-3-окса-9-азониатрицикло[3.3.1.0]нонанбромид, способ его получения, а также его применение для получения лекарственного средства, прежде всего для получения лекарственного средства, обладающего антихолинергическим действием.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200401142A 2002-03-20 2003-03-10 Микронизированный кристаллический тиотропийбромид EA007064B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10212264A DE10212264A1 (de) 2002-03-20 2002-03-20 Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
PCT/EP2003/002422 WO2003078429A1 (de) 2002-03-20 2003-03-10 Kristallines mikronisat des tiotropiumbromids

Publications (2)

Publication Number Publication Date
EA200401142A1 true EA200401142A1 (ru) 2005-04-28
EA007064B1 EA007064B1 (ru) 2006-06-30

Family

ID=27797948

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200401142A EA007064B1 (ru) 2002-03-20 2003-03-10 Микронизированный кристаллический тиотропийбромид

Country Status (37)

Country Link
EP (3) EP1487832B9 (ru)
JP (1) JP4331619B2 (ru)
KR (2) KR101094091B1 (ru)
CN (2) CN101220025A (ru)
AR (1) AR039017A1 (ru)
AT (1) ATE369365T1 (ru)
AU (1) AU2003212327B2 (ru)
BR (1) BRPI0308513B8 (ru)
CA (1) CA2479652C (ru)
CO (1) CO5611105A2 (ru)
CY (2) CY1106923T1 (ru)
DE (2) DE10212264A1 (ru)
DK (2) DK1785422T3 (ru)
EA (1) EA007064B1 (ru)
EC (1) ECSP045310A (ru)
ES (2) ES2615460T3 (ru)
HK (1) HK1078871A1 (ru)
HR (1) HRP20040855B1 (ru)
HU (1) HUE031876T2 (ru)
IL (2) IL163841A0 (ru)
LT (1) LT1785422T (ru)
ME (1) ME02764B (ru)
MX (1) MXPA04009056A (ru)
MY (1) MY139720A (ru)
NO (2) NO346754B1 (ru)
NZ (1) NZ535808A (ru)
PE (1) PE20030838A1 (ru)
PL (1) PL220730B1 (ru)
PT (2) PT1785422T (ru)
RS (1) RS57551B1 (ru)
SA (1) SA03240098B1 (ru)
SI (1) SI1487832T2 (ru)
TW (1) TWI345975B (ru)
UA (1) UA78295C2 (ru)
UY (1) UY27725A1 (ru)
WO (1) WO2003078429A1 (ru)
ZA (1) ZA200405636B (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
SI2067779T1 (sl) 2003-11-03 2013-08-30 Boehringer Ingelheim International Gmbh Tiotropijeve soli, postopek za njihovo pripravo in formulacije zdravil, ki jih vsebujejo
RS20060293A (en) 2003-11-03 2008-08-07 Boehringer Ingelheim International Gmbh., Novel tiotropium salts, methods for the production thereof, and pharmaceutical formulations containing the same
DE102004024451A1 (de) 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
RU2007144531A (ru) * 2005-05-02 2009-06-10 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Новые кристаллические формы тиотропийбромида
DK1881980T3 (da) 2005-05-02 2012-10-01 Boehringer Ingelheim Int Nye krystalline former af tiotropiumbromid
ES2530991T3 (es) 2005-08-15 2015-03-09 Boehringer Ingelheim Int Procedimiento para la obtención de betamiméticos
US20070086957A1 (en) * 2005-10-10 2007-04-19 Thierry Bouyssou Combination of medicaments for the treatment of respiratory diseases
DE102005059602A1 (de) 2005-12-14 2007-06-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Mikronisierung
EP2123650B1 (en) * 2005-12-19 2012-04-04 Sicor, Inc. Novel form of tiotropium bromide and process for preparation thereof
US9108962B2 (en) 2005-12-19 2015-08-18 Sicor, Inc. Forms of tiotropium bromide and processes for preparation thereof
CN100999521B (zh) * 2006-01-13 2010-12-08 江苏正大天晴药业股份有限公司 结晶性抗胆碱药噻托溴铵
GB0716026D0 (en) 2007-08-16 2007-09-26 Norton Healthcare Ltd An inhalable medicament
WO2011093815A2 (en) * 2010-01-29 2011-08-04 Mahmut Bilgic Pharmaceutical compositions comprising formoterol and mometasone
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
PT106142B (pt) * 2012-02-10 2014-07-18 Hovione Farmaci Ncia S A Processo para a preparação de brometo de tiotrópio
EA036153B1 (ru) 2012-07-05 2020-10-06 Арвен Айлак Санайи Ве Тиджарет А.С. Фармацевтическая композиция для ингаляции, упакованная дозированная форма, капсула, способ лечения обструктивных заболеваний дыхательных путей и фармацевтический набор
EP2705838A1 (en) * 2012-09-06 2014-03-12 Xspray Microparticles Ab Tiotropium preparations
EP2897955B1 (en) * 2012-09-11 2019-11-06 Bilgic, Mahmut New tiotropium bromide crystalline form
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
EA037332B1 (ru) 2014-09-09 2021-03-15 Вектура Лимитед Композиция, содержащая гликопирролат, способ и устройство
EP3159278A1 (en) * 2015-10-23 2017-04-26 Arven Ilac Sanayi Ve Ticaret A.S. Blister for tiotropium bromide inhalable formulation
EA034467B1 (ru) * 2015-10-23 2020-02-11 Арвен Иладж Санайи Ве Тиджарет А.Ш. Блистер для ингаляционного состава тиотропия бромида
CN115737610B (zh) * 2021-12-13 2024-02-27 苏州欧米尼医药有限公司 一种噻托溴铵吸入粉雾剂及其活性成分的气流粉碎方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
PH26882A (en) 1985-07-30 1992-11-16 Glaxo Group Ltd Devices for administering medicaments to patients
US5610163A (en) 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
DE3931041C2 (de) * 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
DE4318455A1 (de) 1993-06-03 1994-12-08 Boehringer Ingelheim Kg Kapselhalterung
DE19515625C2 (de) * 1995-04-28 1998-02-19 Boehringer Ingelheim Kg Verfahren zur Herstellung von enantiomerenreinen Tropasäureestern
FR2779347A1 (fr) * 1998-06-05 1999-12-03 Arlette Guerry Procede de micronisation de substances medicamenteuses
NZ509489A (en) 1998-08-04 2002-10-25 Jago Res A Medicinal aerosol formulations comprising cromoglycic acid and/or nedocromil
SK284889B6 (sk) * 1998-11-13 2006-02-02 Jago Research Ag Použitie stearátu horečnatého v suchých práškových formuláciách na inhaláciu
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
WO2000064468A2 (en) † 1999-04-23 2000-11-02 Research Corporation Technologies Therapeutic compositions and methods for enhancing angiogenesis
JP4691298B2 (ja) 1999-10-12 2011-06-01 科研製薬株式会社 粉末吸入用製剤及びその製造方法
NZ525733A (en) 2000-10-12 2005-01-28 Boehringer Ingelheim Pharma Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament
DZ3477A1 (ru) 2000-10-12 2002-04-18
DE10126924A1 (de) 2001-06-01 2002-12-05 Boehringer Ingelheim Pharma Inhalationskapseln
IL159238A0 (en) 2001-06-22 2004-06-01 Boehringer Ingelheim Pharma Crystalline anticholinergic, method for its production, and use thereof in the production of a drug
US7309707B2 (en) 2002-03-20 2007-12-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
US7244842B2 (en) 2002-11-15 2007-07-17 Orchid Chemicals & Pharmaceuticals Ltd. Amorphous hydrate of a cephalosporin antibiotic
DE102005059602A1 (de) 2005-12-14 2007-06-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Mikronisierung
CN102127069A (zh) 2010-01-20 2011-07-20 鲁南制药集团股份有限公司 噻托溴铵晶体

Also Published As

Publication number Publication date
WO2003078429A1 (de) 2003-09-25
CN1642952A (zh) 2005-07-20
IL163841A (en) 2015-10-29
PT1487832E (pt) 2007-08-27
NO20044003L (no) 2004-10-14
EA007064B1 (ru) 2006-06-30
CA2479652C (en) 2012-07-10
ES2615460T3 (es) 2017-06-07
BRPI0308513B1 (pt) 2016-04-19
JP4331619B2 (ja) 2009-09-16
PT1785422T (pt) 2017-02-17
EP1785422A8 (de) 2010-06-23
NO344427B1 (no) 2019-12-02
CO5611105A2 (es) 2006-02-28
DE50307883D1 (de) 2007-09-20
SI1487832T2 (sl) 2018-11-30
BRPI0308513B8 (pt) 2021-05-25
DK1785422T3 (en) 2017-02-27
HRP20040855A2 (en) 2005-06-30
ATE369365T1 (de) 2007-08-15
ES2291619T3 (es) 2008-03-01
MY139720A (en) 2009-10-30
MEP46708A (en) 2011-02-10
DK1487832T4 (en) 2018-12-10
CY1118855T1 (el) 2018-01-10
ES2291619T5 (es) 2018-12-07
UY27725A1 (es) 2003-10-31
TWI345975B (en) 2011-08-01
DE10212264A1 (de) 2003-10-02
HRP20040855B1 (en) 2012-11-30
PE20030838A1 (es) 2003-11-21
NO20190824A1 (no) 2004-10-14
EP1785422B1 (de) 2016-11-16
BR0308513A (pt) 2005-01-04
EP1487832B2 (de) 2018-08-29
CY1106923T1 (el) 2012-09-26
MXPA04009056A (es) 2005-01-25
HUE031876T2 (en) 2017-08-28
EP1487832B9 (de) 2019-01-23
DK1487832T3 (da) 2007-11-05
NO346754B1 (no) 2022-12-12
SI1487832T1 (sl) 2007-12-31
NZ535808A (en) 2005-09-30
KR101021430B1 (ko) 2011-03-15
CN101220025A (zh) 2008-07-16
CA2479652A1 (en) 2003-09-25
EP1487832A1 (de) 2004-12-22
AU2003212327B2 (en) 2009-02-05
AR039017A1 (es) 2005-02-02
CN100368410C (zh) 2008-02-13
EP1785422A1 (de) 2007-05-16
ME02764B (me) 2011-05-10
RS57551B1 (sr) 2018-10-31
PL220730B1 (pl) 2015-12-31
KR101094091B1 (ko) 2011-12-15
KR20100135983A (ko) 2010-12-27
TW200305421A (en) 2003-11-01
EP1487832B1 (de) 2007-08-08
KR20050008662A (ko) 2005-01-21
HK1078871A1 (en) 2006-03-24
AU2003212327A1 (en) 2003-09-29
EP3053921A1 (de) 2016-08-10
ZA200405636B (en) 2006-01-25
ECSP045310A (es) 2004-10-26
LT1785422T (lt) 2017-02-10
SA03240098B1 (ar) 2008-03-24
JP2005526776A (ja) 2005-09-08
PL371799A1 (en) 2005-06-27
UA78295C2 (en) 2007-03-15
IL163841A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
EA200401142A1 (ru) Микронизированный кристаллический тиотропийбромид
EA200301293A1 (ru) Кристаллическое антихолинергическое средство, способ его получения и его применение для получения лекарственного средства
EA200300457A1 (ru) Кристаллический моногидрат, способ его получения и его применение для получения лекарственного средства
EA200300666A1 (ru) Способ получения обладающего антихолинергическим действием тиотропийбромида
UY27751A1 (es) Método para la administración de un anticolinérgico por inhalación
IE873355L (en) N-substituted carboxamides
CY1105543T1 (el) Σκευασματα εναιωρηματων με hfa που περιεχουν αντιχολινεργικο
MEP47308A (en) Hfa-suspension formulation of an anhydrate
MEP54208A (en) Medicaments containing steroids and a novel anticholinesterase drug
IT1260444B (it) Derivati della 8-(1-amminocicloalchil)1,3-dialchilxantina, procedimenbto di preparazione e loro composizioni farmaceutiche antidepressive, nootropiche e psicostimolanti
AR036131A1 (es) Derivados de benzo (g) quinolina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la fabricacion de un medicamento
ECSP034921A (es) Anticolinérgico cristalino, metodo para su producción, y uso del mismo en la producción de una droga

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM